GILEAD SCIENCES SL
- Country
- πͺπΈSpain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT00644761
- Locations
- πΊπΈ
University of Miami, Miami, Florida, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
πΊπΈUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States
Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT00645294
- Locations
- π¬π§
King's College Hospital, London, England, United Kingdom
π©πͺStandort Lindwurmstrasse, Munchen, Germany
π΅π±Klinika Gastroenterologii, Warszawa, Poland
An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
- Conditions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 172
- Registration Number
- NCT00644332
- Locations
- πΊπΈ
Total Heart Care, PC, New York, New York, United States
πΊπΈSouth Denver Cardiology Associates, PC, Littleton, Colorado, United States
πΊπΈJacksonville Center for Clinical Research, Jacksonville, Florida, United States
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2008-06-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 140
- Registration Number
- NCT00643968
- Locations
- π«π·
France and French West Indies, Paris, France
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT00642291
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
- Conditions
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 38
- Registration Number
- NCT00617305
- Locations
- πΊπΈ
Scott & White Memorial Hospital, Temple, Texas, United States
πΊπΈUniversity of Iowa, Iowa City, Iowa, United States
πΊπΈEmory University, Atlanta, Georgia, United States
ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2010-08-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 159
- Registration Number
- NCT00615810
- Locations
- π¬π§
Gilead Sciences, Granta Park, Cambridge, Abington, United Kingdom
ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 115
- Registration Number
- NCT00615745
- Locations
- π¬π§
Gilead Sciences, Cambridge, United Kingdom
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 19
- Registration Number
- NCT00603668
- Locations
- πΊπΈ
M. D. Anderson Cancer Center, Orlando, Florida, United States
πΊπΈUniversity of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT00603863
- Locations
- πΊπΈ
Christiana Care Health Services, Newark, Delaware, United States
πΊπΈUniversity of North Carolina, Chapel Hill, North Carolina, United States
πΊπΈSylvester Comprehensive Cancer Center, Miami, Florida, United States